Last reviewed · How we verify

NCT05246449: VitalCare

Evaluate the Benefit of an Individualised Treatment Plan (VitalCare) VS SOC in OSA Patients Treated With CPAP/APAP

Completed NA Last updated 10 September 2025
What this trial tests

NA trial testing individualised treatment plan (VitalCare) and associated remote medical monitoring in Obstructive Sleep Apnoea Syndrome (OSAS) in 113 participants. Completed in 30 June 2024.

Timeline
15 February 2022
Primary endpoint
15 February 2023
30 June 2024

Quick facts

Lead sponsorAir Liquide Santé International
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposehealth services research
Enrollment113
Start date15 February 2022
Primary completion15 February 2023
Estimated completion30 June 2024
Sites1 location across Portugal

Drugs / interventions tested

Conditions studied

Sponsor

Air Liquide Santé International — full company profile →

Who can join

18 and older, any sex, with Obstructive Sleep Apnoea Syndrome (OSAS). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

According to a stratification procedure, the objective of a personalised care plan (VitalCare) is to identify points for improvement since the early stage of the patient's pathway of CPAP/APAP treatment and to adjust patient follow-up .

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Air Liquide Santé International trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05246449.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing